Pseudomembranous colitis due to Clostridium difficile as a cause of perineal necrotising fasciitis

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Duburcq, Thibault ^a   Parmentier Decrucq, Erika ^a   Poissy, Julien ^a   Mathieu, Daniel ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM; BOTULINUM TOXIN A; BOTULINUM TOXIN B; FLUCONAZOLE; METRONIDAZOLE; NORADRENALIN; PIPERACILLIN PLUS TAZOBACTAM; PYRIMIDINE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN;

ABDOMINAL DISTENSION; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ASCITES; CASE REPORT; CLOSTRIDIUM DIFFICILE; COLITIS; COLONOSCOPY; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DEBRIDEMENT; DIARRHEA; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FECES CULTURE; FEMALE; FEVER; GENERAL CONDITION DETERIORATION; HUMAN; HYPERBARIC OXYGEN; HYPOALBUMINEMIA; INFLAMMATION; INTENSIVE CARE UNIT; INTRAOPERATIVE PERIOD; NECROTIZING FASCIITIS; PANCOLITIS; PANCYTOPENIA; PERINEAL NECROTISING FASCIITIS; PHARYNGITIS; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; SEPTIC SHOCK; SIDEROBLASTIC ANEMIA; SKIN NECROSIS; SURGICAL DRAINAGE; THROMBOCYTE TRANSFUSION;

EID: 84874488991     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-008153     Document Type: Article

References (31)

1. Libby DB, Bearman G. Bacteremia due to Clostridium difficile - review of the literature. Int J Infect Dis 2009;13:e305-9.
2. Ray P, Das A, Singh K, et al. Clostridium tertium in necrotizing fasciitis and gangrene. Emerg Infect Dis 2003;9:1347-9.
3. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390-7. (Pubitemid 30084537)
4. Warny M, Vaerman JP, Avesani V, et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994;62:384-9. (Pubitemid 24033753)
5. Green RJ, Dafoe DC, Raffin TA. Necrotizing fasciitis. Chest 1996;110:219-29. (Pubitemid 26249326)
6. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 2007;44:705-10.
7. Edlich RF, Cross CL, Dahlstrom JJ, et al. Modern concepts of the diagnosis and treatment of necrotizing fasciitis. J Emerg Med 2010;39:261-5.
8. Mathieu D. Hyperbaric oxygen for the treatment of necrotizing fasciitis. Ann Dermatol Venereol 2001;128:411-18. (Pubitemid 32318863)
9. Mathieu D, Nevière R, Lefebvre-Lebleu N, et al. Anaerobic infections of the soft tissues. Ann Chir 1997;51:272-87.
10. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-40.
11. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1-23.
12. Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care 2007;13:450-5. (Pubitemid 47015782)
13. Ali SO, Welch JP, Dring RJ. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 2008;74:20-6. (Pubitemid 351396878)
14. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363-72. (Pubitemid 34183887)
15. Greenstein AJ, Byrn JC, Zhang LP, et al. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery 2008;143:623-9.
16. Lamontagne F, Labbé A-C, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007;245:267-72. (Pubitemid 46148486)
17. Butala P, Divino CM. Surgical aspects of fulminant Clostridium difficile colitis. Am J Surg 2010;200:131-5.
18. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-90. (Pubitemid 40720807)
19. Pepin J, Alary M-E, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7. (Pubitemid 40720808)
20. Zar FA, Bakkanagari SR, Moorthi KMLST, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile - associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7. (Pubitemid 47101025)
21. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile - associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-77.
22. Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect (Larchmt) 2011;12:235-9.
23. Cianci P. Consensus development conference on diabetic foot wound care: a randomized controlled trial does exist supporting use of adjunctive hyperbaric oxygen therapy. Diabetes care 2000;23:873-4.
24. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690-6. (Pubitemid 35024729)
25. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62. (Pubitemid 24034138)
26. Levecq H, Cerf M. Antibiotic associated diarrhea. Ann Gastroenterol Hepatol (Paris) 1990;26:147-56.
27. Mohammedi I, Gachot B, Souweine B, et al. Severe forms of pseudomembranous colitis caused by Clostridium difficile. Ann Fr Anesth Reanim 1995;14:362-5.
28. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile - induced mortality in hamsters. Infect Immun 2006;74:6339-47. (Pubitemid 44657416)
29. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205.
30. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366-70. (Pubitemid 27428197)
31. Taylor CP, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 2008;26:3404-9.